¼¼°èÀÇ ½Å°æÅë Ä¡·á ½ÃÀå : Ä¡·áº°, ÃÖÁ¾ ¿ëµµº°, ±¹°¡º°, Áö¿ªº° »ê¾÷ ºÐ¼®, ½ÃÀå ±Ô¸ð, ½ÃÀå Á¡À¯À², ¿¹Ãø(2025-2032³â)
Neuralgia Treatment Market, By Treatment, By End Use, By Country, and By Region - Global Industry Analysis, Market Size, Market Share & Forecast from 2025-2032
»óǰÄÚµå : 1808945
¸®¼­Ä¡»ç : AnalystView Market Insights
¹ßÇàÀÏ : 2025³â 09¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 322 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 3,250 £Ü 4,605,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠺Ұ¡´ÉÇϸç, ÅØ½ºÆ®ÀÇ Copy&Pasteµµ ºÒ°¡´ÉÇÕ´Ï´Ù.
US $ 4,650 £Ü 6,589,000
PDF (5 User License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷Àå¿¡¼­ 5¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 5,650 £Ü 8,006,000
PDF & Excel (Enterprise User License) help
PDF & Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ ³» ¸ðµç »ç¿ëÀÚ°¡ »ç¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ®ÀÇ Copy&Paste °¡´ÉÇÕ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

½Å°æÅë Ä¡·á ½ÃÀåÀÇ ±Ô¸ð´Â 2024³â¿¡ 26¾ï 9,591¸¸ ´Þ·¯¿´À¸¸ç 2025³âºÎÅÍ 2032³â±îÁö ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR) 7.20%·Î È®´ëµÉ Àü¸ÁÀÔ´Ï´Ù.

½Å°æÅë Ä¡·á´Â ºÎ»ó, °¨¿° ¹× ±âŸ ÀÇÇÐÀû ¹®Á¦·Î ÀÎÇÑ ½Å°æÀÇ ¸¸¼º ÅëÁõÀ» Ư¡À¸·Î ÇÏ´Â º´¸®ÇÐÀÇ Ä¡·á ºÐ¾ßÀÔ´Ï´Ù. ½Å°æÅë Ä¡·á´Â Áõ»óÀ» ¿ÏÈ­Çϰí, Áõ»óÀÇ ÁøÇàÀ» ´ÊÃ߸ç, ÇÕº´ÁõÀ» ÇÇÇϱâ À§ÇØ ½ÃÇàµË´Ï´Ù.

½Å°æÅë Ä¡·á ½ÃÀå - ½ÃÀå ¿ªÇÐ

¸¸¼º ÁúȯÀÇ À¯º´·ü Áõ°¡°¡ ½ÃÀå ¼ºÀåÀÇ ¿øµ¿·Â

´ç´¢º´°ú °°Àº ¸¸¼º ÁúȯÀÇ À¯º´·ü Áõ°¡´Â ½Å°æÅë Ä¡·á ½ÃÀåÀÇ ÇâÈÄ ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ¸¸¼º ÁúȯÀº 1³â ÀÌ»ó Áö¼ÓµÇ´Â ¹®Á¦·Î Áö¼ÓÀûÀÎ ÀÇ·á°¡ ÇÊ¿äÇϰųª, ÀÏ»ó »ýȰÀ» Á¦ÇÑÇϰųª, ȤÀº µÑ ´Ù¿¡ ÇØ´çµÇ´Â Áúº´ÀÔ´Ï´Ù. ´ç´¢º´Àº Ç÷´çÀ¸·Îµµ ¾Ë·ÁÁø °íÇ÷´çÀ» Ư¡À¸·Î ÇÏ´Â ¸¸¼º ´ë»ç ÁúȯÀÔ´Ï´Ù. ½Å°æÅëÀÇ Ä¡·á´Â ´ç´¢º´ ȯÀÚ¿¡¼­ ¹ß»ýÇÒ ¼ö ÀÖ´Â ½Å°æ ¼Õ»óÀÎ ´ç´¢º´¼º ½Å°æ Àå¾Ö¸¦ °³¼±½Ãų ¼ö ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, ½ºÀ§½º¿¡ º»ºÎ¸¦ µÎ°í ÀÖ´Â À¯¿£ Àü¹®±â°üÀÎ ¼¼°èº¸°Ç±â±¸(WHO)´Â 2023³â 9¿ù¿¡ 4,100¸¸ ¸íÀÌ »ç¸ÁÇÏ°í ¼¼°èÀÇ ºñ°¨¿°¼º Áúȯ(NCDs) ¶Ç´Â ¸¸¼º ÁúȯÀ¸·Î ÀÎÇÑ Àü »ç¸ÁÀÇ 74%¸¦ Â÷ÁöÇß´Ù°í º¸°íÇß½À´Ï´Ù. ±× °á°ú, ´ç´¢º´ µîÀÇ ¸¸¼º ÁúȯÀÇ À¯º´·ü Áõ°¡°¡ ½Å°æÅë Ä¡·á ½ÃÀåÀÇ ¼ºÀåÀ» °¡¼ÓÇϰí ÀÖ½À´Ï´Ù.

½Å°æÅë Ä¡·á ½ÃÀå - ¼¼ºÐÈ­ ºÐ¼®

¼¼°èÀÇ ½Å°æÅë Ä¡·á ½ÃÀåÀº Ä¡·á, ÃÖÁ¾ ¿ëµµ, Áö¿ª¿¡ µû¶ó ±¸ºÐµË´Ï´Ù.

½ÃÀåÀº Ä¡·á¿¡ µû¶ó ¾à¹° ¿ä¹ý°ú ¼ö¼ú ¿ä¹ýÀÇ µÎ °¡Áö ¹üÁÖ·Î ³ª´¹´Ï´Ù. 2025³â¿¡´Â ¼ö¼ú ºÎ¹®ÀÌ ½ÃÀåÀ» µ¶Á¡ÇÒ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù. ·Îº¿¿¡ ÀÇÇÑ ¹æ»ç¼± ¼ö¼ú°ú °°Àº Á¤È®ÇÏ°í ºñħ½ÀÀûÀÎ Ä¡·á ¿É¼Ç¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡´Â ÀÌ ºÎ¹®ÀÇ ÁÖ¿ä ÃËÁø ¿äÀÎÀÔ´Ï´Ù. ÀÌ·¯ÇÑ Ã·´Ü ¹æ¹ýÀº ±âÁ¸ÀÇ ¾à¹° ¿ä¹ý°ú ħ½À ¼ö¼úÀÇ Çʿ伺À» ÁÙÀ̸鼭 Ç¥ÀûÀ» Á¼Èù ÅëÁõ ¿ÏÈ­¸¦ Á¦°øÇÕ´Ï´Ù. ·Îº¿¿¡ ÀÇÇÑ ¹æ»ç¼± ¼ö¼úÀº ÁÖº¯ Á¶Á÷¿¡ ´ëÇÑ ¼Õ»óÀ» ÃÖ¼ÒÈ­Çϸ鼭 ³ôÀº Á¤¹Ðµµ¸¦ Á¦°øÇÏ¿© ȯÀÚÀÇ ¿¹Èĸ¦ °³¼±ÇÕ´Ï´Ù. ȯÀÚ°¡ ´õ ¾ÈÀüÇϰí È¿°úÀûÀÎ Ä¡·á¹ýÀ» ã°í Àֱ⠶§¹®¿¡ ħ½À¼ºÀÌ ³·Àº Ä¡·á¹ýÀ¸·ÎÀÇ ÀüȯÀÌ ½ÃÀåÀ» °ßÀÎÇϰí ÀÖ½À´Ï´Ù.

½ÃÀåÀº ÃÖÁ¾ »ç¿ë¿¡ µû¶ó º´¿ø, Ŭ¸®´Ð, ¿Ü·¡¼ö¼ú¼¾ÅÍ(ASC) ¹× ±âŸ À¯ÇüÀ¸·Î ºÐ·ùµË´Ï´Ù. 2025³â¿¡´Â º´¿ø ¹× Ŭ¸®´Ð ºÎ¹®ÀÌ ÃÖ´ë ½ÃÀå ¼öÀÍ Á¡À¯À²À» Â÷ÁöÇÒ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù. º´¿ø ¹× Ŭ¸®´Ð¿¡¼­ °íµµ·Î ºñħ½ÀÀûÀÎ ±â¼úÀ» äÅÃÇÏ¸é º¸´Ù Á¤È®Çϰí Ä¡¹ÐÇÑ Ä¡·á°¡ °¡´ÉÇÏ¸ç ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ±â¼úÀº ħ½ÀÀûÀÎ Ä¡·áÀÇ Çʿ伺À» ÁÙÀ̰í ȸº¹ ½Ã°£À» ´ÜÃàÇϸç ȯÀÚÀÇ ºÒÆíÇÔÀ» ÁÙÀÔ´Ï´Ù. °Ç°­ °ü¸® Á¦°ø¾÷ü´Â ´õ ³ôÀº Á¤È®µµ·Î ´õ ³ªÀº °á°ú¸¦ ¾òÀ» ¼ö ÀÖÀ¸¸ç ȯÀÚ ÀüüÀÇ ¸¸Á·µµ¸¦ ³ôÀÏ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Ä§½À¼ºÀÌ ³·Àº ¿É¼ÇÀ¸·Î À̵¿ÇÏ¸é °í±Þ ½Å°æÅë Ä¡·á¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡ÇÕ´Ï´Ù.

½Å°æÅë Ä¡·á ½ÃÀå - Áö¸®Àû ÀλçÀÌÆ®

ºÏ¹ÌÀÇ ½Å°æÅë Ä¡·á ½ÃÀåÀº ´ç´¢º´ ȯÀÚµé »çÀÌ¿¡¼­ ÅëÁõ¼º ´ç´¢º´¼º ¸»ÃʽŰ溴Áõ(PDN)¿Í °°Àº ¸¸¼º ÅëÁõ ÁúȯÀÇ À¯º´·üÀÌ Áõ°¡ÇÏ°í ºñħ½ÀÀûÀ̰í È¿°úÀûÀÎ Ä¡·á¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí Àֱ⠶§¹®¿¡ 2025³â ÃÖ´ë Á¡À¯À²À» Â÷ÁöÇÒ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù. FDA´Â 2024³â 1¿ù À¯Å뼺 ´ç´¢º´¼º ¸»ÃʽŰ溴Áõ¿¡ ´ëÇÑ Neuralace Medical»çÀÇ ºñħ½ÀÀû Axon Therapy¸¦ ½ÂÀÎÇß½À´Ï´Ù. ÀÌ ½ÂÀÎÀº »çÁö ½Å°æÅëÀÌ ÀÖ´Â ´ç´¢º´ ȯÀÚÀÇ ÅëÁõ °ü¸®¸¦ ÃËÁøÇÕ´Ï´Ù. Axon Therapy´Â ÀúÀü¾Ð Àü±â ÆÞ½º·Î ½Å°æÀ» ÀÚ±ØÇÏ¿© ¾à¹°À̳ª ¼ö¼ú¾øÀÌ ÅëÁõÀ» ¿ÏÈ­ÇÕ´Ï´Ù. ÀÌ Ä¡·á¹ýÀº ´õ ¾ÈÀüÇÏ°í »ç¿ëÇϱ⠽±±â ¶§¹®¿¡ ¸¸¼º ½Å°æ º´¼º ÅëÁõÀÌ ÀÖ´Â ¸¹Àº ´ç´¢º´ ȯÀÚ¸¦ ±¸ÇÒ ¼ö ÀÖ½À´Ï´Ù.

¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ½Å°æÅë Ä¡·á ½ÃÀåÀº ¿¹Ãø ±â°£ µ¿¾È °¡Àå ºü¸£°Ô ¼ºÀåÇÒ Àü¸ÁÀÔ´Ï´Ù. ±ÔÁ¦´ç±¹ÀÇ ½ÂÀÎÀ» ¹ÞÀº Çõ½ÅÀûÀÎ Ä¡·á ¼Ö·ç¼ÇÀº ÀÌ Áö¿ª¿¡¼­ ½Å°æ º¹±¸ ¼ö¼ú ¿É¼ÇÀ» Áõ°¡½Ã۰í ÀÖ½À´Ï´Ù. Àç»ý ÀÇ·á ±â¾÷ÀÎ Orthocell Ltd.´Â ½Ì°¡Æ÷¸£ÀÇ HSA(Health Sciences Authority)·ÎºÎÅÍ RemplirÀÇ ±ÔÁ¦´ç±¹ ½ÂÀÎÀ» ¹Þ¾ÒÀ¸¸ç CY25ÀÇ 1ºÐ±âºÎÅÍ ÆÇ¸Å¸¦ ½ÃÀÛÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÇ·á±â±â °ø±Þ¾÷ü·Î À¯¸íÇÑ µð¹ÙÀ̽º Å×Å©³î·ÎÁö½º´Â ÀÌ ½ÂÀÎ ÀÌÀü¿¡ È£ÁÖ ¹× ´ºÁú·£µå¿¡¼­ Remplir¸¦ ÆÇ¸ÅÇß½À´Ï´Ù. Remplir Äݶó°Õ ·¦Àº ½Å°æ º¹±¸ ¼ö¼úÀ» Çâ»ó½Ãŵ´Ï´Ù.

½Å°æÅë Ä¡·á ½ÃÀå - °æÀï ±¸µµ

½Å°æÅë Ä¡·á ½ÃÀåÀÇ °æÀïÀº Áß°£ Á¤µµÀ̸ç, È­ÀÌÀÚ, ±Û¶ô¼Ò ½º¹Ì½ºÅ©¶óÀÎ, ³ë¹ÙƼ½º, ¹ÙÀÌ¿ÀÁ¨ÀÌ Ç×°æ·ÃÁ¦, Ç׿ì¿ïÁ¦, ±¹¼Ò ÁøÅëÁ¦·Î ÀǾàǰ ºÎ¹®À» Áö¹èÇϰí ÀÖ½À´Ï´Ù. ±Û·Î¹ö½º ¸ÞµðÄÿ¡ ÀÇÇÑ ³×ºê·Î»çÀÇ Àμö µî ½Å°æ Á¶Àý Á¦Ç°ÀÇ È®ÃæÀ» ¸ñÀûÀ¸·Î ÇÑ Á¦ÈÞ¿Í ÇÕº´µµ ´Ã°í ÀÖ½À´Ï´Ù. ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ¼±µµ±â¾÷µéµµ °Ç°­ °ü¸®¿¡ ´ëÇÑ Á¢±Ù¼ºÀÌ °³¼±µÇ°í Ä¡·áºñ°¡ Àú·ÅÇØÁü¿¡ µû¶ó »ó½ÂÇϰí ÀÖ½À´Ï´Ù. Àü¹ÝÀûÀ¸·Î, Ç¥Àû ¾à¹° ¿ä¹ý, Àúħ½À ÅëÁõ °ü¸® ¼Ö·ç¼ÇÀÇ Áøº¸, °³ÀÎÈ­ Ä¡·á Á¢±Ù¹ýÀÇ È°¿ë È®´ë·Î ÀÌ ½ÃÀåÀÌ Çü¼ºµÇ°í ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå ½Å°æÅë Ä¡·á ½ÃÀå °³¿ä

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½Å°æÅë Ä¡·áÀÇ ÁÖ¿ä ½ÃÀå µ¿Çâ

Á¦4Àå ½Å°æÅë Ä¡·á »ê¾÷ÀÇ Á¶»ç

Á¦5Àå ½Å°æÅë Ä¡·á ½ÃÀå : ³ô¾ÆÁö´Â ÁöÁ¤ÇÐÀû ±äÀåÀÇ ¿µÇâ

Á¦6Àå ½Å°æÅë Ä¡·á ½ÃÀå »óȲ

Á¦7Àå ½Å°æÅë Ä¡·á ½ÃÀå - Ä¡·áº°

Á¦8Àå ½Å°æÅë Ä¡·á ½ÃÀå - ÃÖÁ¾ ¿ëµµº°

Á¦9Àå ½Å°æÅë Ä¡·á ½ÃÀå - Áö¿ª

Á¦10Àå ÁÖ¿ä º¥´õ ºÐ¼® - ½Å°æÅë Ä¡·á ¾÷°è

Á¦11Àå ¾Ö³Î¸®½ºÆ®ÀÇ Á¾ÇÕÀû Àü¸Á

CSM
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Neuralgia Treatment Market size was valued at US$ 2,695.91 Million in 2024, expanding at a CAGR of 7.20% from 2025 to 2032.

Neuralgia treatment is the treatment of a medical condition characterized by chronic pain in the nerves that can be caused by injury, infection, or other medical issues. Neuralgia treatment is used to alleviate symptoms, slow the progression of the condition, and avoid complications.

Neuralgia Treatment Market- Market Dynamics

Growing Prevalence Of Chronic Diseases Fuels Market Growth

The increasing prevalence of chronic diseases, such as diabetes, is expected to drive future growth in the neuralgia treatment market. Chronic diseases are problems that last a year or more and require ongoing medical care, limit daily activities, or both. Diabetes is a chronic metabolic condition characterized by high blood glucose, also known as blood sugar. Neuralgia treatment can help with diabetic neuropathy, which is nerve damage that can occur in people with diabetes. For instance, the World Health Organization, a United Nations specialized agency based in Switzerland, reported 41 million deaths in September 2023, accounting for 74% of all deaths caused by noncommunicable diseases (NCDs) or chronic diseases worldwide.As a result, the increasing prevalence of chronic diseases such as diabetes is driving the growth of the neuralgia treatment market.

Neuralgia Treatment Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 7.20% over the forecast period (2025-2032)

According to treatment segmentation, the year 2025 is expected to see the highest market share for surgery.

According to End Use segmentation, the most common End Use in 2025 will be hospitals and clinics.

North America ranked as the top revenue-generating region in 2025.

Neuralgia Treatment Market- Segmentation Analysis:

The Global Neuralgia Treatment Market is segmented on the basis of Treatment, End Use, and Region.

The market is divided into two categories based on Treatment: Drug Based, and Surgery. The surgery segment will dominate the market in 2025. The growing demand for precise, non-invasive treatment options, such as robotic radiosurgery, is a major driver in the segment. These advanced methods provide targeted pain relief while reducing the need for traditional medications or invasive surgeries. Robotic radiosurgery allows for high accuracy while causing minimal damage to surrounding tissues, which improves patient outcomes. The market is being driven by a shift toward less invasive treatments, as patients seek safer, more effective alternatives.

The market is divided into three categories based on End Use: Hospital & Clinics, Ambulatory Surgery Centers, and Others. In 2025, the hospital and clinics segment will account for the largest market revenue share. Adoption of advanced, non-invasive technologies in hospitals and clinics drives market growth by allowing for more precise and targeted treatments. These technologies reduce the need for invasive procedures, resulting in faster recovery times and less patient discomfort. Healthcare providers can achieve better results with greater precision, increasing overall patient satisfaction. This shift toward less invasive options increases demand for advanced neuralgia treatments.

Neuralgia Treatment Market- Geographical Insights

North America neuralgia treatment market will hold the largest share in 2025 due to the rising prevalence of chronic pain conditions like painful diabetic neuropathy (PDN) among diabetics, driving demand for non-invasive, effective treatments. The FDA approved Neuralace Medical's non-invasive Axon Therapy for painful diabetic neuropathy in January 2024. This approval advances pain management for diabetics with limb nerve pain. Axon Therapy stimulates nerves with low-voltage electrical pulses to reduce pain without drugs or surgery. The therapy may help many diabetics with chronic neuropathic pain by being safer and more accessible.

Asia Pacific neuralgia treatment market to grow fastest over forecast period. Innovative treatment solutions approved by regulators have increased nerve repair surgery options in the region. Orthocell Ltd., a regenerative medicine company, received regulatory approval from Singapore's Health Sciences Authority (HSA) for Remplir, allowing sales to begin in Q1 of CY25. Device Technologies, a well-known medical device supplier, distributed Remplir in Australia and New Zealand before this approval. Remplir collagen wraps improve nerve repair surgery.

Neuralgia Treatment Market- Competitive Landscape:

The Neuralgia Treatment Market is moderately competitive, with Pfizer, GlaxoSmithKline, Novartis, and Biogen dominating the pharmaceutical segment with anticonvulsants, antidepressants, and topical analgesics. The market is seeing more collaboration and mergers, such as Globus Medical's acquisition of Nevro, to expand its neuromodulation offerings. Regional players in Asia-Pacific are also gaining ground as healthcare access improves and therapies become more affordable. Overall, the landscape is shaped by advances in targeted drug therapies, minimally invasive pain management solutions, and the growing use of personalized treatment approaches.

Recent Developments:

In January 2024, Zydus Lifesciences has received final FDA approval for its generic Gabapentin tablets for the treatment of postherpetic neuralgia (PHN). The approval covers 300 mg and 600 mg once-daily doses of a drug used to relieve pain after shingles.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL NEURALGIA TREATMENT MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

GLOBAL NEURALGIA TREATMENT MARKET, BY TREATMENT- MARKET ANALYSIS, 2019 - 2032

GLOBAL NEURALGIA TREATMENT MARKET, BY END USE- MARKET ANALYSIS, 2019 - 2032

GLOBAL NEURALGIA TREATMENT MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

Table of Contents

1. Neuralgia Treatment Market Overview

2. Executive Summary

3. Neuralgia Treatment Key Market Trends

4. Neuralgia Treatment Industry Study

5. Neuralgia Treatment Market: Impact of Escalating Geopolitical Tensions

6. Neuralgia Treatment Market Landscape

7. Neuralgia Treatment Market - By Treatment

8. Neuralgia Treatment Market - By End Use

9. Neuralgia Treatment Market- By Geography

10. Key Vendor Analysis- Neuralgia Treatment Industry

11. 360 Degree AnalystView

12. Appendix

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â